A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Hyperhidrosis Clinical Trial

Official title:

A Randomized, Double Blinded, Vehicle-Controlled Study to Evaluate the Safety and the Effect on Sweat Production of Topically Applied BBI-4000 in Subjects With Hyperhidrosis.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02058264
• Other study ID #: BBI-4000-CL-101
• Status: Completed
• Phase: Phase 1
• Start date: February 2014
• Est. completion date: September 2014

Study information

• Verified date: December 2022
• Source: Botanix Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics and treatment effect of BBI-4000 when topically applied to subjects with axillary hyperhidrosis.

Description:

This is a randomized, vehicle controlled, double blind study in subjects with axillary hyperhidrosis designed to assess the safety, tolerability and the effect on sweat production of topically applied BBI-4000 for 14 days.

Safety will be assessed though vital signs, physical exam, adverse events, local skin reactions and laboratory tests (blood chemistry and hematology).

Efficacy will be assessed though the gravimetrically measured sweat production and the Hyperhidrosis Disease Severity Score (HDSS).

Pharmacokinetic information will also be collected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: September 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Male or Female subjects from 18 to 45 years of age in good general health.

• Primary axillary hyperhidrosis of at least 6 months duration.

• Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline.

• Gravimetric test at baseline indicating at least 100mg of axillary sweat production in a 5 min period.

• Use of a medically appropriate contraceptive method.

Exclusion Criteria:

• Prior axillary use of botulinum toxin within 2 years of study entry.

• Prior iontophoresis treatment for axillary hyperhidrosis within 12 weeks of study entry.

• Prior surgical procedures for hyperhidrosis or surgical procedures in the axillary areas for any reason.

• Use of anticholinergic treatment, beta-blocker, alpha-adrenergic or other prescription treatment for hyperhidrosis.

• History of diabetes mellitus, thyroid disease, malignancy, glaucoma, intestinal obstructive or motility disease, obstructive uropathy, myasthenia gravis, prostate hypertrophy, neurological conditions or cardiac abnormalities.

• Known condition that may cause hyperhidrosis.

• Use of an investigational drug within 30 days prior to entry into this study.

Related Conditions & MeSH terms

• Hyperhidrosis

Intervention

Drug:
• BBI-4000

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Botanix Pharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent change in the gravimetrically measured sweat production from baseline		Week 2
Secondary	Absolute change in the gravimetrically measured sweat production from baseline		Week 2
Secondary	Proportion of subjects who have a minimum of 2-grade improvement in HDSS from baseline.		Week 2
Secondary	Proportion of subjects who have a minimum of 1-grade improvement in HDSS from baseline		Week 2